Profiles

Keywords
Last Name
Institution

Reem Karmali

Title
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Hematology, Oncology and Cell Therapy
AddressChicago IL 60678
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, Fenske TS, Sauter C, Kharfan-Dabaja MA, Awan FT. Higher total body irradiation dose-intensity in fludarabine/TBI-based reduced-intensity conditioning regimen is associated with inferior survival in non-Hodgkin lymphoma patients undergoing allogeneic transplantation: Flu/2Gy TBI vs Flu/4Gy TBI in NHL. Biol Blood Marrow Transplant. 2020 Mar 09. PMID: 32165327.
      View in: PubMed
    2. Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Adv. 2020 Jan 28; 4(2):253-262. PMID: 31945157.
      View in: PubMed
    3. Landsburg DJ, Ayers EC, Bond DA, Maddocks KJ, Karmali R, Behdad A, Curry M, Wagner-Johnston ND, Modi D, Ramchandren R, Assouline SE, Faramand R, Chavez JC, Torka P, Mier Hicks A, Medeiros LJ, Li S. Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. Br J Haematol. 2019 Dec 05. PMID: 31804715.
      View in: PubMed
    4. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M. Allogeneic transplantation in elderly patients =65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 12 03; 9(12):97. PMID: 31796726.
      View in: PubMed
    5. Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 Jan 15; 126(2):293-303. PMID: 31568564.
      View in: PubMed
    6. Karmali R, Gordon LI. Revving up the immune engine in cHL. Blood. 2019 07 04; 134(1):1-2. PMID: 31273001.
      View in: PubMed
    7. Behdad A, Boddy CS, Fought AJ, Taxter T, Falkiewicz MK, Ayers E, Chen QC, Chen YH, Karmali R, Pro B, Winter JN, Landsburg DJ, Gordon LI, Kaplan JB. Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. Leuk Lymphoma. 2019 Dec; 60(13):3266-3271. PMID: 31225766.
      View in: PubMed
    8. Burkart M, Schieber M, Basu S, Shah P, Venugopal P, Borgia JA, Gordon L, Karmali R. Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. Br J Haematol. 2019 Jul; 186(1):45-53. PMID: 30941741.
      View in: PubMed
    9. Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836. PMID: 30707764.
      View in: PubMed
    10. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. J Clin Oncol. 2019 02 20; 37(6):471-480. PMID: 30615550.
      View in: PubMed
    11. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leuk Lymphoma. 2019 Apr; 60(4):940-946. PMID: 30277110.
      View in: PubMed
    12. Schieber M, Gordon LI, Karmali R. Current overview and treatment of mantle cell lymphoma. F1000Res. 2018; 7. PMID: 30109020.
      View in: PubMed
    13. Chukkapalli V, Gordon LI, Venugopal P, Borgia JA, Karmali R. Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells. Oncotarget. 2018 Apr 20; 9(30):21166-21181. PMID: 29765528.
      View in: PubMed
    14. Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018 06 15; 124(12):2541-2551. PMID: 29645093.
      View in: PubMed
    15. Kanis MJ, Zielenbach M, Karmali R, Peevey J, Blanco LZ, Horowitz JM, Lurain JR. Painless Vulvar Masses as Initial Manifestation of Marginal Zone Lymphoma. J Low Genit Tract Dis. 2018 Jan; 22(1):82-84. PMID: 29271861.
      View in: PubMed
    16. Karmali R, Chukkapalli V, Gordon LI, Borgia JA, Ugolkov A, Mazar AP, Giles FJ. GSK-3ß inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget. 2017 Dec 29; 8(70):114924-114934. PMID: 29383130.
      View in: PubMed
    17. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 11 15; 123(22):4411-4418. PMID: 28749548.
      View in: PubMed
    18. Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS. Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2017 07; 17(7):408-414. PMID: 28756899.
      View in: PubMed
    19. Fidler MJ, Frankenberger C, Seto R, Lobato GC, Fhied CL, Sayidine S, Basu S, Pool M, Karmali R, Batus M, Lie WR, Hayes D, Mistry J, Bonomi P, Borgia JA. Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy. Oncotarget. 2017 Aug 29; 8(35):58108-58121. PMID: 28938541.
      View in: PubMed
    20. Karmali R, Alrifai T, Fughhi IAM, Ng R, Chukkapalli V, Shah P, Basu S, Nathan S, Szymanski-Grant K, Gordon LI, Venugopal P, Penedo FJ, Borgia JA. Impact of cachexia on outcomes in aggressive lymphomas. Ann Hematol. 2017 Jun; 96(6):951-956. PMID: 28417157.
      View in: PubMed
    21. Richardson K, Alrifai T, Grant-Szymanski K, Kouris GJ, Venugopal P, Mahon B, Karmali R. Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature. Mol Clin Oncol. 2017 Apr; 6(4):539-542. PMID: 28413663.
      View in: PubMed
    22. Karmali R, Larson ML, Shammo JM, Gregory SA, O'Brien T, Venugopal P. Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma. Mol Clin Oncol. 2017 Apr; 6(4):627-633. PMID: 28413681.
      View in: PubMed
    23. Karmali R, Nabhan C, Petrich AM, Raizer J, Peace D, Lukas R, Gordon LI, Basu S, Chukkapalli V, Venugopal P. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. Br J Haematol. 2017 Apr; 177(1):72-79. PMID: 28211579.
      View in: PubMed
    24. Karmali R, Gordon LI. Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy. Curr Treat Options Oncol. 2017 02; 18(2):11. PMID: 28229364.
      View in: PubMed
    25. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. Am J Hematol. 2017 Feb; 92(2):161-170. PMID: 27880984.
      View in: PubMed
    26. Alrifai T, Grant Szymanski K, Venugopal P, Mahon B, Okwuosa T, Karmali R. Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20. Chemotherapy. 2017; 62(2):140-146. PMID: 27960150.
      View in: PubMed
    27. Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 12; 16(12):672-678. PMID: 27660080.
      View in: PubMed
    28. Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao W, Vanslambrouck C, Nabhan C. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Br J Haematol. 2016 Nov; 175(4):631-640. PMID: 27469075.
      View in: PubMed
    29. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016 09 10; 34(26):3141-9. PMID: 27269951.
      View in: PubMed
    30. Karmali R, Larson ML, Shammo JM, Basu S, Christopherson K, Borgia JA, Venugopal P. Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42. PMID: 25735964.
      View in: PubMed
    31. Karmali R, Dalovisio A, Borgia JA, Venugopal P, Kim BW, Grant-Szymanski K, Hari P, Lazarus H. All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies. Blood Rev. 2015 Mar; 29(2):71-80. PMID: 25433571.
      View in: PubMed
    32. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Oct 09; 124(15):2354-61. PMID: 25161267.
      View in: PubMed
    33. Kellogg RG, Straus DC, Karmali R, Munoz LF, Byrne RW. Impact of therapeutic regimen and clinical presentation on overall survival in CNS lymphoma. Acta Neurochir (Wien). 2014 Feb; 156(2):355-65. PMID: 24078063.
      View in: PubMed
    34. Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW. Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. J Leukoc Biol. 2013 Jan; 93(1):161-70. PMID: 23136257.
      View in: PubMed
    35. Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012 Jan 19; 119(3):692-5. PMID: 22117038.
      View in: PubMed
    36. Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM. Analysis of very elderly (=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012 Jan; 156(2):196-204. PMID: 22084970.
      View in: PubMed
    37. Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2011 Nov; 52(11):2097-104. PMID: 21702643.
      View in: PubMed
    38. Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74. PMID: 21700527.
      View in: PubMed
    39. Karmali R, Farhat M, Leslie W, McIntire MG, Gregory S. Localized bone disease as a presentation of hairy cell leukemia. Clin Adv Hematol Oncol. 2008 Apr; 6(4):290-4. PMID: 18496495.
      View in: PubMed
    Karmali's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description